Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588300980> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2588300980 endingPage "vi428" @default.
- W2588300980 startingPage "vi428" @default.
- W2588300980 abstract "The primary analysis of this open-label, randomized, multicenter, phase 2 study found significantly longer progression-free survival (PFS) for pemetrexed plus gefitinib (P + G) vs gefitinib alone (G) in 191 East Asian patients with EGFR mt+ NS NSCLC (adjusted hazard ratio [HR]: 0.68; 95% confidence interval [CI]: 0.48-0.96; P = 0.029). Translational research, interim OS data and updated safety results are reported. Treatment-naive patients with advanced, EGFR mt+ (local laboratory testing), NS NSCLC were randomized (2:1) to receive P + G (pemetrexed 500 mg/m2, Day 1 of 21-day cycles plus gefitinib 250 mg/day; n = 126) or G (gefitinib 250 mg/day; n = 65). Mandatory pretreatment tissue samples were assayed for EGFR mutations by central evaluation (CE) (n = 159) and thymidylate synthase (TS) by immunohistochemistry (n = 146). OS in the intention-to treat (ITT) population and correlation of biomarkers with clinical outcomes were analyzed by adjusted Cox regression. By CE, 149/159 patients (93.7%) were EGFR mt+. In the CE+ population, PFS was longer for P + G (n = 96) vs G (n = 53) (HR: 0.72; 95% CI: 0.48-1.06; P = 0.093), consistent with the primary analysis based on local testing. In patients with low (n = 67) and high (n = 79) TS expression, the PFS HR was 0.47 (95% CI: 0.26-0.87) and 0.83 (95% CI: 0.47-1.46), respectively; the interaction effect was not statistically significant (P = 0.177). At the interim OS analysis (80 events, 58% censoring), OS was not significantly different for P + G vs G (HR: 0.79; 95% CI: 0.49-1.28; P = 0.342). Postdiscontinuation systemic therapy was common (P + G: 62.7%; G: 72.3%). The incidence of grade 3/4 drug-related adverse events was significantly (P = 0.002) higher for P + G (42.9%) vs G (20.0%). The PFS HR for the CE+ population was consistent with the primary ITT analysis. No significant interaction effects were seen for TS. At this interim analysis, there was no statistical difference in OS for P + G vs G. Final OS analyses will be reported when 130 events have occurred." @default.
- W2588300980 created "2017-02-24" @default.
- W2588300980 creator A5008159291 @default.
- W2588300980 creator A5010499363 @default.
- W2588300980 creator A5024261346 @default.
- W2588300980 creator A5025707585 @default.
- W2588300980 creator A5028033679 @default.
- W2588300980 creator A5031434066 @default.
- W2588300980 creator A5038009127 @default.
- W2588300980 creator A5047320061 @default.
- W2588300980 creator A5048333692 @default.
- W2588300980 creator A5055074037 @default.
- W2588300980 creator A5057704753 @default.
- W2588300980 creator A5074447759 @default.
- W2588300980 creator A5075008348 @default.
- W2588300980 creator A5085174655 @default.
- W2588300980 date "2016-10-01" @default.
- W2588300980 modified "2023-09-27" @default.
- W2588300980 title "Randomized phase 2 trial of gefitinib with and without pemetrexed as first-line therapy in East Asian patients with advanced, epidermal growth factor receptor (EGFR) mutation-positive (mt+), nonsquamous (NS) non-small cell lung cancer (NSCLC): Translational research and interim overall survival (OS)" @default.
- W2588300980 doi "https://doi.org/10.1093/annonc/mdw383.40" @default.
- W2588300980 hasPublicationYear "2016" @default.
- W2588300980 type Work @default.
- W2588300980 sameAs 2588300980 @default.
- W2588300980 citedByCount "0" @default.
- W2588300980 crossrefType "journal-article" @default.
- W2588300980 hasAuthorship W2588300980A5008159291 @default.
- W2588300980 hasAuthorship W2588300980A5010499363 @default.
- W2588300980 hasAuthorship W2588300980A5024261346 @default.
- W2588300980 hasAuthorship W2588300980A5025707585 @default.
- W2588300980 hasAuthorship W2588300980A5028033679 @default.
- W2588300980 hasAuthorship W2588300980A5031434066 @default.
- W2588300980 hasAuthorship W2588300980A5038009127 @default.
- W2588300980 hasAuthorship W2588300980A5047320061 @default.
- W2588300980 hasAuthorship W2588300980A5048333692 @default.
- W2588300980 hasAuthorship W2588300980A5055074037 @default.
- W2588300980 hasAuthorship W2588300980A5057704753 @default.
- W2588300980 hasAuthorship W2588300980A5074447759 @default.
- W2588300980 hasAuthorship W2588300980A5075008348 @default.
- W2588300980 hasAuthorship W2588300980A5085174655 @default.
- W2588300980 hasBestOaLocation W25883009801 @default.
- W2588300980 hasConcept C121608353 @default.
- W2588300980 hasConcept C123321153 @default.
- W2588300980 hasConcept C126322002 @default.
- W2588300980 hasConcept C143998085 @default.
- W2588300980 hasConcept C168563851 @default.
- W2588300980 hasConcept C207103383 @default.
- W2588300980 hasConcept C2776694085 @default.
- W2588300980 hasConcept C2777240266 @default.
- W2588300980 hasConcept C2778239845 @default.
- W2588300980 hasConcept C2779438470 @default.
- W2588300980 hasConcept C2780258809 @default.
- W2588300980 hasConcept C2780456651 @default.
- W2588300980 hasConcept C2780580887 @default.
- W2588300980 hasConcept C2908647359 @default.
- W2588300980 hasConcept C31760486 @default.
- W2588300980 hasConcept C44249647 @default.
- W2588300980 hasConcept C61943457 @default.
- W2588300980 hasConcept C71924100 @default.
- W2588300980 hasConcept C99454951 @default.
- W2588300980 hasConceptScore W2588300980C121608353 @default.
- W2588300980 hasConceptScore W2588300980C123321153 @default.
- W2588300980 hasConceptScore W2588300980C126322002 @default.
- W2588300980 hasConceptScore W2588300980C143998085 @default.
- W2588300980 hasConceptScore W2588300980C168563851 @default.
- W2588300980 hasConceptScore W2588300980C207103383 @default.
- W2588300980 hasConceptScore W2588300980C2776694085 @default.
- W2588300980 hasConceptScore W2588300980C2777240266 @default.
- W2588300980 hasConceptScore W2588300980C2778239845 @default.
- W2588300980 hasConceptScore W2588300980C2779438470 @default.
- W2588300980 hasConceptScore W2588300980C2780258809 @default.
- W2588300980 hasConceptScore W2588300980C2780456651 @default.
- W2588300980 hasConceptScore W2588300980C2780580887 @default.
- W2588300980 hasConceptScore W2588300980C2908647359 @default.
- W2588300980 hasConceptScore W2588300980C31760486 @default.
- W2588300980 hasConceptScore W2588300980C44249647 @default.
- W2588300980 hasConceptScore W2588300980C61943457 @default.
- W2588300980 hasConceptScore W2588300980C71924100 @default.
- W2588300980 hasConceptScore W2588300980C99454951 @default.
- W2588300980 hasLocation W25883009801 @default.
- W2588300980 hasOpenAccess W2588300980 @default.
- W2588300980 hasPrimaryLocation W25883009801 @default.
- W2588300980 hasRelatedWork W1967058699 @default.
- W2588300980 hasRelatedWork W1975425037 @default.
- W2588300980 hasRelatedWork W2073784779 @default.
- W2588300980 hasRelatedWork W2136403887 @default.
- W2588300980 hasRelatedWork W2136894251 @default.
- W2588300980 hasRelatedWork W2153397369 @default.
- W2588300980 hasRelatedWork W2358450743 @default.
- W2588300980 hasRelatedWork W3029973176 @default.
- W2588300980 hasRelatedWork W4254666574 @default.
- W2588300980 hasRelatedWork W4310754086 @default.
- W2588300980 hasVolume "27" @default.
- W2588300980 isParatext "false" @default.
- W2588300980 isRetracted "false" @default.
- W2588300980 magId "2588300980" @default.
- W2588300980 workType "article" @default.